Cryoglobulinemia vasculitis: An update

Current Opinion in Rheumatology

Volumn 25, Issue 1, 2013, Pages 10-18

  Terrier, Benjamin ^a,b,c,d   Cacoub, Patrice ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b Unit of Dermatology   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cryoglobulinemia; hepatitis C virus; prognosis; treatment; vasculitis

Indexed keywords

AZATHIOPRINE; BOCEPREVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; LENALIDOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PEGINTERFERON ALPHA; PREDNISONE; RIBAVIRIN; RITUXIMAB; TELAPREVIR; THALIDOMIDE;

CLINICAL FEATURE; CRYOGLOBULINEMIA VASCULITIS; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HUMAN; INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMALL VESSEL VASCULITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CRYOGLOBULINEMIA; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; PROGNOSIS; VASCULITIS;

EID: 84871228991     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835b15f7     Document Type: Review

References (38)

1. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204-2212.
2. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study ofetiologicfactorsand clinical and immunologicfeatures in 443 patientsfrom a single center. Medicine (Baltimore) 2001; 80:252-262.
3. Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risksoflymphomaand death among patients with nonhepatitis Cvirus-related mixed cryoglobuline-mia. Arch Intern Med 2006; 166:2101-2108.
4. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57:775-788.
5. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287-308.
6. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55:4-13.
7. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the Cryo Vas survey. Blood 2012; 119:5996-6004.
8. Terrier B, Carrat F, Krastinova E, et al. Prognosticfactorsof survival in patients with noninfectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the Cryo Vas survey. Ann Rheum Dis 2012. [Epub ahead of print]
9. Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: New insights based on 64 cases. Medicine (Baltimore) 2012 (in press).
10. Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011; 63:1748-1757.
11. Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40:837-856.
12. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-{alpha}, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116:343-353.
13. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-{alpha}/ribavirin compared with Peg-interferon-{alpha}/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116:326-334.
14. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011; 70:1183-1190.
15. Quartuccio L, Isola M, Corazza L, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifesta-tions in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012; 30:S48-S52.
16. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618-623.
17. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demo-graphic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355-374.
18. Della Rossa A, Tavoni A, D'Ascanio A, et al. Mortalityrateand outcomefactors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheu-matol 39:167-170.
19. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
20. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19-27.
21. Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987; 83:726-730.
22. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46:3317-3326.
23. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviraltherapyforhepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54:3696-3706.
24. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis Cvirus infection. Blood 1997; 90:3865-3873.
25. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobu-linemiaassociated with hepatitis Cvirus. N Engl J Med 1994; 330:751-756.
26. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84:3336-3343.
27. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
28. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alphawith an anti-CD20. Blood 2003; 101:3818-3826.
29. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Ne-phrol Dial Transplant 2004; 19:3054-3061.
30. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinae-mia vasculitis. Ann Rheum Dis 2008; 67:1431-1436.
31. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60:2531-2540.
32. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843-853.
33. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglo-bulinemic vasculitis. Arthritis Rheum 2012; 64:835-842.
34. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) 2010; 62:1787-1795.
35. Gottenberg JE, Ravaud P, Bardin T, et al. Riskfactors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62:2625-2632.
36. Payet J, Livartowski J, Kavian N, et al. Type Icryoglobulinemiainmultiplemyeloma, arareentity:analysisofclinicaland biologicalcharacteristicsofsevencasesand review of the literature. Leuk Lymphoma 2012. [Epub ahead of print]
37. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 2005; 44:410-411.
38. Pandrangi S, Singh A, Wheeler DE, Rossi NF. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Ne-phrol 2008; 4:393-397.